Abstract
BackgroundAutologous bone marrow cell transplantation (BMCs-Tx) is a promising novel option for treatment of cardiovascular disease. In this study we analyzed whether intracoronary autologous freshly isolated BMCs-Tx have beneficial effects on cardiac function in patients with ischemic heart disease (IHD).ResultsIn this prospective nonrandomized study we treated 12 patients with IHD by freshly isolated BMCs-Tx by use of point of care system and compared them with a representative 12 control group without cell therapy. Global ejection fraction (EF) and infarct size area were determined by left ventriculography.Intracoronary transplantation of autologous freshly isolated BMCs led to a significant reduction of infarct size (p < 0.001) and an increase of global EF (p = 0.003) as well as infarct wall movement velocity (p < 0.001) after 6 months follow-up compared to control group. In control group there were no significant differences of global EF, infarct size and infarct wall movement velocity between baseline and 6 months after coronary angiography. Furthermore, we found significant decrease in New York Heart Association (NYHA) as well as significant decrease of B-type natriuretic peptide (BNP) level 6 months after intracoronary cell therapy (p < 0.001), whereas there were no significant differences in control group 6 months after coronary angiography.ConclusionsThese results demonstrate that intracoronary transplantation of autologous freshly isolated BMCs by use of point of care system is safe and may lead to improvement of cardiac function in patients with IHD.Trial registrationRegistration number: ISRCTN54510226
Highlights
Autologous bone marrow cell transplantation (BMCs-Tx) is a promising novel option for treatment of cardiovascular disease
98 ± 1.5 infarct wall movement velocity between the two groups (Tables 3 and 4). 6 months after cell therapy, we observed a significant increase of global ejection fraction (EF) and infarct wall movement velocity compared to baseline
We observed significant decrease in New York Heart Association (NYHA) classification and B-type natriuretic peptide (BNP) levels 6 months after intracoronary cell therapy, whereas there were no significant differences in control group 6 months after coronary angiography (Table 3 and 4)
Summary
Autologous bone marrow cell transplantation (BMCs-Tx) is a promising novel option for treatment of cardiovascular disease. In this study we analyzed whether intracoronary autologous freshly isolated BMCs-Tx have beneficial effects on cardiac function in patients with ischemic heart disease (IHD). Cardiac performance after myocardial infarction is compromised by ventricular remodelling, which represents a major cause of late infarct-related chronic heart failure and death [1,2]. Conventional drug therapy may delay remodelling, there is no basic therapeutic regimen available for preventing or even reversing this process. By the use of interventional therapeutics, recanalization of the occluded infarct-related artery is possible, thereby improving or prospective nonrandomized control trial, we analyzed the influence of intracoronary freshly isolated cell therapy by use of point of care system on cardiac function in patients with ischemic heart disease (IHD)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
